Innate lymphoid cells (ILCs) have emerged as a key cell type involved in surveillance and maintenance of mucosal tissues. Mouse ILCs rely on the transcriptional regulator Inhibitor of DNA-binding protein 2 (Id2) for their development. Here, we show that Id2 also drives development of human ILC because forced expression of Id2 in human thymic progenitors blocked T cell commitment, upregulated CD161 and promyelocytic leukemia zinc finger (PLZF), and maintained CD127 expression, markers that are characteristic for human ILCs. Surprisingly CD5 was also expressed on these in vitro generated ILCs. This was not an in vitro artifact because CD5 was also found on ex vivo isolated ILCs from thymus and from umbilical cord blood. CD5 was also expressed on small proportions of ILC2 and ILC3. CD5 + ILCs were functionally immature, but could further differentiate into mature CD5 − cytokine-secreting ILCs. Our data show that Id2 governs human ILC development from thymic progenitor cells toward immature CD5 + ILCs.
, and it is plausible that such precursors may also develop into ILCs. Previously, we documented that lineage commitment of the bipotential thymic T/NK progenitors is dependent on the balanced expression levels of E-proteins, which are members of the basic helix-loop-helix (bHLH) transcription factor family, and their antagonist Id proteins (10, 11) . Id2 is a member of a family of Helix-loop-helix factors consisting of four members, Id1, Id2, Id3, and Id4, which share the capacity of sequestering bHLH transcription factors, including E2A and HEB, which are needed for T and B cell development, and E2-2, required for development of plasmacytoid dendritic cells (pDC) (12) (13) (14) (15) . As a consequence, Id proteins can inhibit T and B cell and pDC development (10, 11, 16, 17) . High levels of Id2 results in NK cell development by suppressing E2A and HEB activity, whereas a high ratio of E2A and HEB to Id2 favors T cell development (15) . Id proteins inhibit T and B cell development at an early stage by blocking upregulation of RAG1 and RAG2 genes thereby prohibiting T cell receptor and B cell receptor rearrangements (10, 11, 16) . This may set the stage for development of the precursors to ILCs. Indeed ILCs require expression of Id2 for their development, as its deficiency resulted in the complete absence of all ILCs in mice (18) .
In addition to Id2, several other transcription factors have been identified that are required for mouse ILC development. Nuclear factor interleukin 3 (Nfil3) and thymocyte selection associated high mobility group box protein (TOX) are required for differentiation of the common lymphoid progenitor (CLP) into the integrin α4β7-expressing ILC progenitor α lymphoid precursor (αLP) (19) (20) (21) (22) (23) . αLPs further differentiate into common helper ILC progenitors, which are progenitors of ILC1, ILC2, ILC3, and LTi cells, and promyelocytic leukemia zinc finger (PLZF) expressing ILC precursors (ILCp), which have lost the ability to develop into LTi cells, but retain potential to develop into the remaining ILC subsets (24, 25) . The intermediate stages between stem cells and mature ILC in humans are less well defined. Recent studies in humans identified a potential ILCp displaying a RORγt + CD34 + phenotype in tonsils and intestinal lamina propria that differentiated into IL-22 producing ILC3 (5) . Another group identified a population of progenitor cells expressing RORγt and IL-1R1, the receptor for IL-1β, in secondary lymphoid tissues that differentiated into all ILCs, including NK cells, but not into T cells or DCs (6) . More recently, a c-kit + ILCp was identified in peripheral blood of humans that in vitro could develop into all mature ILC subsets (26) . As these cells were also found in various organs it was proposed that these circulating c-kit + ILC are able to home in the tissues and to develop into mature ILC in those tissues.
In the present study, we examined the capacity of Id2 to promote development of human ILC. We demonstrate that ectopic expression of Id2 blocked T cell differentiation, resulting in ILCs that expressed CD5 and intracellular (ic) CD3. In vitro generated ILCs expressing CD5 and icCD3 phenocopied ILCs that can be found in vivo in thymus and cord blood. Ex vivo isolated CD5 + non-T cells showed typical features of ILCs and displayed a functionally immature phenotype based on their inability to produce cytokines upon activation. CD5
+ immature ILCs could be induced to differentiate into cytokine-producing CD5 − ILCs in vitro.
MaTerials anD MeThODs

Monoclonal antibodies and cytokines
The following antibodies to human proteins were used. From BioLegend: fluorescein isothiocyanate (FITC)-conjugated antiCD1a (HI149), anti-CD3 (OKT3), anti-CD4 (RPA-T4) anti-CD14 (HCD14), anti-CD16 (3G8), anti-CD19 (HIB19), anti-CD34 (581), anti-CD94 (DX22), anti-CD123 (6H6), anti-FcER1α (AER-37); phycoerythrin (PE)-conjugated anti-CD161 (HP-3G10), anti-NKp44 (P44-8), anti-IL-5 (JES1-39D10); Alexa Fluor 647-conjugated anti-NKp44 (P44-8); Alexa Fluor (AF) 700-conjugated anti-CD3 (UCHT1), anti-IL-17A (BL168); Allophycocyanin (APC)-conjugated anti-CD3 (OKT3), anti-CD56 (HCD56), anti-CD94 (DX22), anti-IL-13 (JES10-5A2); APC Cy7-conjugated anti-CD4 (OKT4); APC/Fire 750-conjugated anti-CD161 (HP-3G10); brilliant violet (BV) 421-conjugated anti-CD161 (HP-3G10), anti-CD3 (OKT3), anti-CD5 (UCHT2); BV510-conjugated anti-IFN-γ (4S.B3); BV650 streptavidin. From Becton Dickinson: FITC-conjugated anti-CD34 (581), anti-TCRαβ (IP26), ant-TCRγδ (B1), anti-CD8 (SK1); PE-CF594-conjugated anti-CD3 (UCHT1), anti-CRTH2 (BM16); AF647-conjugated anti-CRTH2 (CD294; BM16). From Beckman Coulter: PE-Cy7-conjugated anti-CD127 (R34.34); PE Cy5.5-conjugated anti-CD117 (104D2D1); PE-conjugated antiCD1a (SFCI19Thy1A8). From Miltenyi: FITC-conjugated anti-BDCA2 (CD303; AC144); APC-Vio770-conjugated anti-CD5 (UCHT2). From eBiosciences: PE Cy7-conjugated anti-IL-22 (22URT1). From invitorogen: PE Cy5.5-conjugated anti-CD5 (CD5-5D7). From NIH AIDS research program: purified anti-α4β7. Human cytokines: IL-2 was obtained from Novartis, IL-15, stem cell factor (SCF), IL-1β, IL-6, and TNF-α were obtained from R&D systems (Abingdon, UK). IL-7 and Flt3L were obtained from Pepro Tech, Inc. (Rocky Hill, NJ, USA).
cell lines, constructs, and retrovirus Production
The naïve OP9 murine stromal cell line was kindly provided by Dr. T. Nakano (Osaka University, Osaka, Japan) OP9-Jag1, OP9-Jag2, and OP9-DL1 were generated as previously described (27) . Id2 was isolated from the retroviral construct LZRS Id2 IRES GFP previously described (17) and subcloned into LZRS IRES mCherry by using restriction enzyme NotI (Roche, Germany). The empty construct was used in control transductions. Retroviral supernatant was obtained from transfected Phoenix-GALV packaging cells (28) .
isolation of cD34
+ cells and ilcs from Postnatal Thymus (PnT) and Umbilical cord Blood (UcB)
The use of PNT tissue and umbilical cord blood (UCB) was approved by the Medical Ethical Committee of the Academic Medical Center. Thymocytes were obtained from surgical specimens removed from children up to 3 years of age undergoing open heart surgery and UCB was collected with informed consent of the patients in accordance with the Declaration of Helsinki. The tissue was disrupted by mechanical means and pressed through a stainless steel mesh to obtain a single-cell suspension, which was left overnight at 4°C. , were sorted to purity on a FACSAria (BD Biosciences). For the isolation of ILCs from PNT and UCB, mononuclear cells isolated from a Ficoll-Hypaque density gradient (Lymphoprep; Axis-Shield) were positively selected by labeling with PE-conjugated anti-CD161 (described above) plus anti-PE microbeads (Miltenyi). The CD161 + cells were stained with Abs against Lineage (CD1a, CD3, CD4, CD8, CD14, CD19, CD16, CD34, CD94, CD123, TCRαβ, TCRγδ, FcER1α), CD161, CD127, CD117, CRTH2, NKp44, and CD5. Cells were sorted on a FACSAria, purity of the sorted cells in all experiments was >99%.
retroviral Transduction and Differentiation assay
For transduction experiments, CD34
+
CD1a
− postnatal thymocytes were cultured overnight in Yssel's medium (29) with 5% normal human serum, 20 ng/ml SCF and 10 ng/ml IL-7. The following day cells were incubated for 6-7 h with virus supernatant in retronectin-coated plates (30 µg/ml; Takara Biomedicals, Shiga, Japan). The development of ILCs and NK cells was assessed by coculturing the mixture of transduced and non-transduced CD34
+
CD1a
− progenitor cells with OP9 cells in MEMα medium (Life Technologies, Carlsbad, CA, USA) with 20% FCS (Hyclone Laboratories, Logan, UT, USA), 5 ng/ml SCF, 5 ng/ml IL-7, and 5 ng/ml FLT3L. 0.5 ng/ml IL-15 was added at the onset of the culture, the medium containing IL-15 was refreshed every week. Flow cytometric analyses were performed on a LSRII FACS analyzer (BD Biosciences); electronic gating was performed using FlowJo (Tree Star, Ashland, OR, USA). Numbers in each dot plot represent the percentage of cells in each quadrant. The fold expansion in absolute cell numbers was calculated using Microsoft Excel 2007 (Microsoft, Redmond, WA, USA) on the basis of total numbers of cells harvested from the cultures, percentages of transduced cells, and percentages of each population corrected for the number of input cells.
Quantitative real-time Pcr
Total RNA was extracted with a NucleoSpin RNA XS kit (MachereyNagel) according to the manufacturer's instructions. cDNA was synthesized with a High-Capacity cDNA Archive kit (Applied Biosystems). PCRs were performed in a Bio-Rad iCycler (Bio-Rad, France) with IQ SYBR Green Supermix (Bio-Rad, France) using the following primer sets or otherwise as previously described (30) Id2 forward 5′-TTGTCAGCCTGCATCACCAGAG-3′; Id2 reverse 5′-AGCCACACAGTGCTTTGCTGTC-3′; PLZF forward 5′-GAGCTTCCTGATAACGAGGCTG-3′; PLZF reverse 5′-AG CCGCAAACTATCCAGGAACC-3′; Nfil3 forward 5′-TGGAGA AGACGAGCAACAGGTC-3′; Nfil3 reverse 5′-CTTGTGTGGC AAGGCAGAGGAA-3′; TOX forward 5′-CGCTACCTTTGGC GAAGTCTCT-3′; TOX reverse 5′-CTGGCTCTGTATGCTGCG AGTT-3′. Bio-Rad CFX Manager 3.1 software was used for quantification of expression. All samples were normalized to the expression of GAPDH and results are presented in arbitrary units.
ilc Differentiation, single cell cloning, and expansion
For differentiation assays, isolated ILCs were cultured in Yssel's medium supplemented with 1% (v/v) human AB serum (Invitrogen) for 5-7 days. Cytokines used in these assays were IL-2 (10 U/ml), IL-7 (10 ng/ml), IL-1β (50 ng/ml), IL-6 (50 ng/ml), and TNF-α (50 ng/ml). Single cell or bulk ILCs were expanded in vitro by culturing with 2 × 10 6 /ml irradiated (25 Gy) allogenic peripheral blood mononuclear cells, 2 × 10 5 /ml irradiated (50 Gy) JY Epstein-Barr virus-transformed B cells, phytohemagglutinin (1 µg/ml; Oxoid), IL-2 (100 U/ml), and IL-7 (10 ng/ml) in Yssel's medium.
resUlTs ilcs are Present in Thymus and express id2
We and others have demonstrated that the thymus contains bispecific T/NK cell progenitors (7) (8) (9) 15) . In humans, these cells are contained within CD34 + CD1a − CD5 + cells (9) . We expected that thymic T/NK cell progenitors would also be able to develop into ILC within the thymus. Therefore, we first investigated the presence of ILC subsets in the human thymus. We observed that human thymus contained ILCs at a frequency of approximately 1 in 100,000 total thymocytes. All ILC subsets, ILC1, ILC2, and ILC3 (both NKp44 + and NKp44 − ) were present ( Figures 1A,B ) and that all subsets expressed higher levels of Id2 as compared to CD34
+
CD1a
− thymic progenitor cells ( Figure 1C ).
id2 induces Differentiation of cD161-expressing ilcs
Previously, we have demonstrated that thymic progenitors that overexpress Id2 develop into NK cells in response to IL-15 (15) . Here, we investigated the effect of forced expression of Id2 in thymic precursors on ILC development. Id2-transduced CD34 + CD1a − cells were cocultured with OP9 mouse stromal cells in the presence of IL-7, SCF, and FLT3L. We observed that Id2 increased the development of ILC-like cells that expressed CD127, CD161, and integrin α4β7 (Figures 2A,B) , both in proportion as well as in absolute cell numbers. Consistent with our previous report (15) , Id2 inhibited differentiation into T cells and pDC, showing that the balance between E-proteins and Id2 is important for the cell lineage decision between T cells, pDC, and NK/ILC cells (14, 15, 17) . Like CD127, CD5 was expressed on virtually all thymic progenitor cells and no difference in expression of these antigens was observed between control and Id2 conditions (Figure 2A) . Thus, Id2 transduction resulted in the expansion of a lineage (CD1a, CD3, CD4, CD8, CD94, BDCA2) negative CD5 + CD161 + CD127 + cell population resembling ILCs (Figure 2A ; Figure S1A in Supplementary Material). While 
CD1a
− progenitor cells and NK cells were isolated from PNT and used for negative and positive controls, respectively. all control transduced ILCs expressed c-Kit, only a fraction of the in vitro generated Id2 + ILCs expressed c-Kit, whereas no CRTH2 + ILC2 or NKp44 + ILC3 were detected ( Figure S1A in Supplementary Material). This CD5
+ ILC-like cell population was also generated on OP9 cells expressing the Notch ligands Jagged1 (Jag1), Jagged2 (Jag2) or delta-like 1(DL1), with the highest expansion rate when cells were cultured on OP9-Jag1 (Figures S1A,B in Supplementary Material), indicating that the Notch ligand Jag2 can affect in vitro expansion of Id2 + ILCs, but Notch ligands have little effect on their phenotype. Id2 + (mCherry
+ cells can be divided into three populations based on their CD5 and α4β7 expression ( Figure 2C) . The Id2
+ cells expressing both CD5 and α4β7 lacked cell surface (s) expression of CD3, but expressed high intracellular (ic) CD3 staining, while the cells with CD5, but no α4β7 showed lower icCD3 staining. Our data indicate that whereas Id2 inhibits TCR rearrangement and expression, induction of intracellular expression of CD3 is not prevented by Id2. As ectopic expression of Id2 completely blocks development of T cells by preventing TCR rearrangements (10, 11) , sCD3
− icCD3 + CD5 + should be non-T cells. CD4, which is expressed on immature single positive T cell progenitors (31), was not detected on Id2 + CD5 + ILC ( Figure  S1D in Supplementary Material). Id2-induced ILCs expressed higher levels of PLZF, Nfil3, and TOX transcripts when compared with CD34 + CD1a − progenitor cells, especially the CD5 + α4β7 − ILC population, which had slightly higher expression of PLZF and Nfil3 compared to the CD5 + α4β7 + population ( Figure 2D ).
Nfil3 and TOX expression were not restricted to ILCs as high expression was also detected in both NK and T cells, but PLZF expression was hardly detected in T cells, consistent with the notion that PLZF expressing Id2
The expansion of NK cells by Id2 is strongly increased in the presence of IL-15 ( Figure 2B ). In contrast, no effect of IL-15 was observed on the expansion of the Lin 
CD161
+ cells generated on OP9-Jag1 and cultured these cells with OP9 cells with or without IL-15. We observed no upregulation of the NK cell markers CD94 or CD56. Furthermore, CD127 was not downregulated by IL-15 ( Figure S1C in Supplementary Material). These results indicate that Id2 
cD5 + ilcs are Present in the PnT and UcB
We next investigated the expression of CD5 on ex vivo isolated ILC subsets. We observed that on average 17% of the total thymic ILC population (Lin Figure 3A) . Similar percentages of CD5 + ILCs were detected in UCB ( Figure 3B) . The CD5 expression level on ILCs was lower compared to T cells ( Figure S2B in Supplementary Material). In 
CD1a
− cells and NK cells were used as negative and positive controls, respectively. All qPCR values presented are relative to GAPDH expression. + ILCs expressed CRTH2 and NKp44 in addition to c-Kit, which indicates that CD5 can be expressed on all ILC subsets ( Figure 3B ). In addition, we observed a minor population of α4β7 + cells among CD5 + ILCs ( Figure S2A in Supplementary Material). We tested CD5
+ ILCs from thymus and UCB for ILC related gene expression by qPCR. Similar to CD5 − ILCs, CD5 + ILCs expressed Id2 and PLZF (Figures 3C,D) . In addition, representative transcription factors for each ILC subset, namely T-bet (ILC1), GATA3 (ILC2) and RORγt (ILC3), were expressed at similar levels in the UCB CD5 − and CD5 + ILCs (Figure 3D ).
In contrast to CD5
+ ILCs, CD5 as CD5 is commonly known to be expressed on mature T cells (32) . We found, however, that although part, but not all, of CD5 Thymic and cord Blood cD5 + ilcs are Functionally immature
To assess their ability to produce cytokines, CD5
+ ILCs from thymus were sorted and stimulated with PMA/Ionomycin and analyzed for cytokine gene expression by qPCR (Figure 4A ).
CD5
− ILC subsets were also isolated from the thymus and used as a reference. Notably, CD5
+ ILCs did not express any of the ILC signature cytokine genes after stimulation, whereas CD5 − ILC1 expressed IFNγ, CD5 − ILC2 expressed IL-5 and CD5
− ILC3 expressed IL-17A and IL-22. All ILCs, including CD5
+ ILCs, expressed IL-2, but at lower levels compared to T cells isolated from tonsils ( Figure S3A in Supplementary Material). We further investigated the expression of cytokineencoded genes by UCB CD5 + ILCs. Similarly to thymic CD5 + ILCs, UCB CD5 + ILC either did not respond to stimulation or expressed lower levels of cytokine genes than CD5
− ILC (Figure 4B) . ILC3 related cytokine gene expression was low in both CD5
+ and CD5 − ILC, which is in line with our observation that adult peripheral blood ILC3s lack the ability to produce significant amounts of IL-17A and IL-22 upon activation with PMA and ionomycin ( Figure S3B in Supplementary Material). IL-2 expression was also low in all UCB ILCs compared to T cells from tonsil ( Figure S3A ILCs, total CD5 + ILCs were highly purified from cord blood and cultured for 7 days in the presence of IL-2 and IL-7. We observed that part of CD5 + ILCs lost CD5 expression ( Figure 5A ). This differentiation was also induced when the cells were cultured with IL-1β, TNFα, and IL-6, cytokines typically elevated in the inflammatory state. Even though the cells were isolated at high purity, we still cannot exclude the possibility that CD5 − ILCs appearing in those culture conditions are derived from a minor contamination of CD5 − ILCs. Thus, we deposited single CD5 + ILCs in wells of a microtiter culture plate and generated clones in the presence of irradiated allogenic peripheral blood mononuclear cells and JY cells (feeder cells), IL-2 and IL-7. After 3 weeks of culturing, 65 out of 360 wells showed cell growth equivalent to 17% plating efficiency, making it highly likely that the starting cell number was indeed 1 cell per well as previously demonstrated (33). Among those 65 clones, 5 clones exhibited sCD3 expression (data not shown) and were excluded from further analysis. There were three types of CD5 + ILC-derived clones observed; those which remained CD5 + , those which gave rise to both CD5 + and CD5 − ILCs, and those which became CD5 − ILCs (Figure 5B ). The frequency of those three phenotypes was equally distributed among the clones. This result strongly indicates that CD5
+ ILCs can indeed differentiate into CD5
− ILCs, and confirmed that CD5 − ILCs appearing in differentiation and proliferation assays were derived from CD5 + ILCs.
UcB cD5 − ilc2s are Functionally competent and Derive from cD5 + ilc2s
To assess the functionality of CD5 − ILCs derived from CD5 + precursors, we cultured highly purified cord blood CD5 + ILC2 with feeder cells in the presence of IL-2 and IL-7 ( Figure 6A ) and after 2 weeks determined the production of cytokines and expression of cytokine transcripts by CD5
+ and CD5 − ILC2s following PMA/ionomycin stimulation. A higher frequency of cytokine-producing cells in the CD5
− fraction compare to the CD5 + fraction was observed and cytokine gene expression levels of CD5 + ILC2s and CD5 − ILC2s, derived from CD5 + ILC2s, were significantly different (Figures 6A,B) . To further corroborate that CD5 + ILC2 can differentiate into mature CD5 − ILC2 we performed single cell cloning experiments starting from ILCs that expressed CRTH2 + (Figure 6C) . Consistent with the previous experiments, most of the clones had lost CD5 and were able to produce type 2 cytokines upon stimulation with PMA and ionomycin. In addition to type 2 cytokines, we have also tested type 1 (IFN-γ) and type 3 (IL-17A and IL-22) cytokines. There were no IFN-γ nor IL-17A producing clones observed, suggesting that CD5 + LC2s are ILC2 committed precursors. We observed that many clones produced IL-22 consistent with earlier observations on cultured ILC2 from peripheral blood (34) . These results together indicate that CD5 + ILC2s can differentiate into functionally competent CD5 − ILC2.
DiscUssiOn
Our data show that expression of Id2 in human progenitor cells favors development of ILCs while inhibiting T cell and pDC development (10, 11, 14, 15, 17) . One of the mechanisms by which Id2 inhibits T cell development is preventing TCR gene rearrangements (10). As CD5 was described to be a marker that distinguishes T cells from ILCs (35) it was unexpected to observe that under conditions in which TCR gene rearrangements and thus T cell development is blocked, CD5 + ILCs are generated. These CD5 + ILCs cannot be T cells that have downregulated the expression of TCR, because Id2 prevents TCR gene rearrangements (10) . CD5 expression on ILCs that express ectopic Id2 is not an in vitro artifact, because CD5 + ILCs were also found when isolated ex vivo from thymus and UCB. These cells are distinct from CD5 + T-cell progenitors as they express Id2, which precludes T-cell development, and lack expression of CD1a (12). Moreover, CD5
+ ILC expressed markers that are characteristic of ILCs, including CD127, CD161, Id2, and PLZF. As it was shown that Id2 promoted expression of PLZF during invariant NKT cell development in the mouse (36), our findings support the notion that Id2 may regulate the expression of PLZF to drive human ILC lineage development, but it should be noted that PLZF may be differentially regulated in mouse and human ILC, because unlike mouse ILCs (24) PLZF is also expressed in mature ILCs in humans (37) . A proportion of CD5 + ILCs express icCD3, similar to the CD5 + ILC generated from Id2 overexpressing progenitor cells, but did not express TCRαβ or TCRγδ proteins in the cytoplasm consistent with the fact that Id2 inhibits TCR gene rearrangement. Together with our data of Id2 overexpression, we conclude − CD94 − cells. CD5 + ILCs were isolated from UCB and cultured with IL-2 (10 U/ml) and IL-7(10 ng/ml) or IL-2, IL-7, IL-1β (50 ng/ml), IL-6 (50 ng/ml), and TNFα (50 ng/ml). The data shown are a representative of four independent experiments. (B) Flow cytometry analysis of three representative CD5
+ ILC clones (top), frequency of CD5 expression (bottom). FigUre 6 | UCB CD5 − ILC2s are functionally competent and derive from CD5 + ILC2s. (a) Cytokine production of bulk CD5 + ILC2 after 2 weeks of coculturing with the irradiated allogenic peripheral blood mononuclear cells and JY cell (feeder cells) with IL-2 (100 U/ml) and IL-7 (10 ng/ml). Total cells were stimulated with P/I for 6 h. (B) qPCR analysis of cytokine expression level of CD5 + ILC2 derived CD5 + ILC2s and CD5-ILC2s. Cells were sorted from the feeder cells coculture with IL-2 (100 U/ml) and IL-7 (10 ng/ml) after 2 weeks and unstimulated or stimulated with P/I for 6 h (n = 5). *P < 0.05 (Student's t-test) (c) Single CD5 + CRTH2 + ILC2 cell was sorted and cultured in feeder cells with IL-2 (100 U/ml) and IL-7 (10 ng/ml) for 2 weeks and cytokine production was evaluated after stimulated with P/I for 6 h. ILCs fully differentiate into mature CD5 − ILCs under inflammatory conditions. This notion is supported by our observation that, pro-inflammatory cytokines IL-1β, IL-6, and TNF-α promoted differentiation of CD5 + ILCs into CD5 − ILCs in vitro. It has been reported that SCID patients with IL-2 receptor gamma or JAK3 deficiency not only lack T cells, B cells, and NK cells, but also ILC subsets. After hematopoietic stem cell transplantation in these patients, T cells, B cells, and ILC1-but no other ILC subsets including NK cells-were reconstituted (40) . Interestingly, these reconstituted ILC1 expressed CD5. Given our suggestion that CD5 expression represents an immature stage of ILCs, this may indicate that the CD5 + ILC1s in these patients are arrested from further differentiation into mature ILCs. Recently CD4 + ILC1 were found in peripheral blood (41) . We confirmed those findings and found that those CD4 + ILC1 also expressed CD5 [(42) and Nagasawa, unpublished observation]. However, in contrast, the cord blood and thymic CD5 + ILCs described here, which express CD161, lacked CD4. The relationship between the immature CD5 + ILCs described here and the CD4 + CD5 + ILC1 described previously has yet to be fully established.
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